Skip Navigation
Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

FY 2011 Funding Overview

Appropriations History

  • The NIAID Appropriation decreased 0.9 percent from fiscal year (FY) 2010 to FY 2011.

Mission Areas

  • NIAID’s budget was evenly distributed across three mission areas: $1.7 B for biodefense, $1.5 billion for immunological and immune-mediated diseases, and $1.6 billion for HIV/AIDS.

Funding by Budget Mechanism

  • More than half of NIAID’s budget was allocated to Research Project Grants (RPGs), and more than one quarter was allocated to Research & Development contracts.

Research Project Grants

  • R01 grants were funded to 10th percentile.
  • New investigators were funded to the 14th percentile.
  • 42 percent of total RPGs were R01s.
  • The average cost of a competing RPG was $479,000.
  • 231 grants—totaling $38 million—were funded as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.

Competing and Noncompeting RPG Awards

  • NIAID supported more than 2,800 non-competing grants and nearly 1,000 competing grants.
  • $1.9 billion was allocated for non-competing RPGs and $476 million for competing RPGs.

RPG Application Success Rate

  • NIAID’s RPG application success rate ranged from 20 to 25 percent since 2004.

Training and Career Development Awards by Mechanism

  • NIAID maintained consistent support for training and career development in FY 2011, funding more than 1,500 awards ($97 million).

Funding for Selected Pathogens, Diseases, and Conditions

  • NIAID reports funding levels by pathogen (disease-causing organism), specific disease or condition, and research area

Funded Extramural Research by State

  • NIAID supported research in nearly every state, as well as the District of Columbia and Puerto Rico

Last Updated January 31, 2013

Last Reviewed January 31, 2013